AR066648A1 - Peptido ciclizado por lactamas, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de canceres artritis reumatica, fibrosis pulmonar e infeccion por vih - Google Patents
Peptido ciclizado por lactamas, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de canceres artritis reumatica, fibrosis pulmonar e infeccion por vihInfo
- Publication number
- AR066648A1 AR066648A1 ARP080102137A ARP080102137A AR066648A1 AR 066648 A1 AR066648 A1 AR 066648A1 AR P080102137 A ARP080102137 A AR P080102137A AR P080102137 A ARP080102137 A AR P080102137A AR 066648 A1 AR066648 A1 AR 066648A1
- Authority
- AR
- Argentina
- Prior art keywords
- glu
- group
- absent
- lys
- asp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Péptido ciclizado por lactamas, que es antagonista CXCR4, de formula 1: R1 - ciclo[X1 - Tyr - X3 - dArg - 2Nal - Gly - X7] - X8 - X9 - X10 - R2 (1) (SEQ ID NO : 1) en donde: a) la lactama se forma por un enlace amida entre el grupo amino de cadena lateral de X1 y el grupo carboxilo de cadena lateral de X7, en donde X1 y X7 son, respectivamente, un par seleccionado del grupo que consiste de (D/L)Agl/Glu, Dab/Glu, y Dap/Glu, y R1 es Ac o n-hexanoilo; o b) la lactama se forma por un enlace amida entre el grupo carboxilo de cadena lateral de X1 y el grupo amino de cadena lateral de X7, en donde X1 y X7 son, respectivamente, un par seleccionado del grupo que consiste de Asp/(D/L)Agl, Asp/Dab, Asp/Dap, Glu/(D/L)Agl, Glu/Dab, Glu/Dap, Glu/dDap, y Glu/Lys, y R1 es Ac o Bz, o en donde x1 y x7 son, respectivamente, un par seleccionado del grupo que consiste de succinilo/(D/L)Agl, succinilo/Dab, succinilo/Dap, succinilo/Lys, y succinilo/Orn, y R1 está ausente; o c) la lactama se forma por un enlace amida entre el grupo alfa-amino de X1 y el grupo carboxilo de cadena lateral de x7, en donde X1 y X7 son, respectivamente, un par seleccionado del grupo que consiste de Ala/Glu, Ala/dGlu, dAla/Glu, dAla/dGlu, Dap(Ac)/Glu, Gly/Asp, Gly/Glu, Gly/dGlu, Leu/Glu, Leu/dGlu, Lys/dGlu, Lys(Ac)/Glu, 2Nal/Glu, Phe/Glu, Phe/dGlu, dPhe/Glu, y dphe/dGlu, y R1 está ausente; o d) la lactama se forma por un enlace amida entre un grupo amino no alfa, sin cadena lateral de X1 y el grupo carboxilo de cadena lateral de X7, en donde X1 y X7 son, respectivamente, un par seleccionado del grupo que consiste de beta-Ala/Asp, beta-Ala/Glu, 5-amino-valerilo/Asp, 5-aminovalerilo/Glu, 4-AMB/Glu, 4-AMPA/Asp, y 4-AMPA/Glu, y R1 está ausente; o e) la lactama se forma por un enlace amida entre el grupo alfa-amino de X2 y el grupo carboxilo de cadena lateral de X7, en donde X2 y X7 son, respectivamente, un par seleccionado del grupo que consiste de Tyr/Asp, Tyr/Glu, y Tyr/dGlu, y R1 y X1 están cada uno ausentes; R1 es un sustituyente sobre el grupo alfa-amino de X1 cuando X1 contiene un grupo alfa-amino y el grupo alfa-amino no es un constituyente del enlace amida de la lactama, seleccionado del grupo que consiste de Ac, Bz, y n-hexanoilo, o está ausente, en donde X1 es seleccionado del grupo que consiste de (D/L)Agl, Asp, Dab, Dap, y Glu; X1 es seleccionado del grupo que consiste de (D/L)Agl, Ala, beta-Ala, dAla, 5-aminovalerilo, 4-AMB, 4-AMPA, Asp, Dab, Dap, Dap(Ac), Glu, Gly, Leu, Lys, Lys(Ac), 2Nal, phe, dPhe, y succinilo, o está ausente; X3 es seleccionado del grupo que consiste de Arg, Lys, Lys(iPr), y Lys(Me2); X7 es seleccionado del grupo que consiste de (D/L)Agl, Asp, Dab, Dap, dDap, Glu, dGlu, Lys, y Orn; X8 es seleccionado del grupo que consiste de beta-Ala, Arg, dArg, Gly, Lys, Lys(iPr) y Orn, o está ausente; X9 es seleccionado del grupo que consiste de Gly, 2Nal, d2Nal, y dPhe, o está ausente; X10 es 2Nal, o está ausente; en donde cuando X8 está ausente, X9 y X10 están cada uno ausentes, y cuando X9 está ausente, X10 está ausente, y R2 es seleccionado del grupo que consiste de NH2 y NHEt, o una sal farmacéuticamente aceptable del mismo. Composicion farmacéutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de cánceres, artritis reumática, fibrosis pulmonar e infeccion por VIH.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94080207P | 2007-05-30 | 2007-05-30 | |
| US94099607P | 2007-05-31 | 2007-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066648A1 true AR066648A1 (es) | 2009-09-02 |
Family
ID=39831600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102137A AR066648A1 (es) | 2007-05-30 | 2008-05-20 | Peptido ciclizado por lactamas, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de canceres artritis reumatica, fibrosis pulmonar e infeccion por vih |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7691813B2 (es) |
| EP (2) | EP2377579A1 (es) |
| JP (1) | JP5358564B2 (es) |
| KR (2) | KR101319740B1 (es) |
| CN (1) | CN101678213B (es) |
| AR (1) | AR066648A1 (es) |
| AT (1) | ATE516853T1 (es) |
| AU (1) | AU2008260326B2 (es) |
| BR (1) | BRPI0812134A2 (es) |
| CA (1) | CA2688574C (es) |
| CL (1) | CL2008001467A1 (es) |
| CO (1) | CO6241137A2 (es) |
| CR (1) | CR11105A (es) |
| CY (1) | CY1111815T1 (es) |
| DK (1) | DK2160221T3 (es) |
| DO (1) | DOP2009000270A (es) |
| EA (1) | EA017716B1 (es) |
| GT (1) | GT200900304A (es) |
| HK (1) | HK1141474A1 (es) |
| HR (1) | HRP20110551T1 (es) |
| IL (1) | IL201685A (es) |
| JO (1) | JO2776B1 (es) |
| MA (1) | MA31666B1 (es) |
| MX (1) | MX2009012952A (es) |
| MY (1) | MY149432A (es) |
| NZ (1) | NZ580849A (es) |
| PE (1) | PE20090299A1 (es) |
| PL (1) | PL2160221T3 (es) |
| PT (1) | PT2160221E (es) |
| TN (1) | TN2009000496A1 (es) |
| TW (1) | TWI423987B (es) |
| WO (1) | WO2008150689A1 (es) |
| ZA (1) | ZA200908345B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2942798B1 (fr) | 2009-03-05 | 2011-04-08 | Centre Nat Rech Scient | Peptides utilisables pour le traitement de la leucemie lymphoide chronique |
| IT1397901B1 (it) | 2010-01-26 | 2013-02-04 | Consiglio Nazionale Ricerche | Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico. |
| JPWO2012118124A1 (ja) * | 2011-03-01 | 2014-07-07 | 国立大学法人京都大学 | 新規ケモカイン受容体拮抗剤 |
| ES2552944T3 (es) * | 2011-06-07 | 2015-12-03 | Polyphor Ag | Peptidomiméticos de horquilla beta como antagonistas de CXCR4 |
| CN104780930A (zh) * | 2011-09-30 | 2015-07-15 | 程云 | 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用 |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| EP2979991A1 (en) | 2014-07-31 | 2016-02-03 | Greif International Holding BV. | Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat. |
| DK3050574T3 (da) | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
| WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
| EP3509612A4 (en) * | 2016-09-06 | 2021-07-21 | Mainline Biosciences | CXCR4 ANTAGONISTS AND METHOD OF USE |
| CN106841624B (zh) * | 2017-01-26 | 2019-02-22 | 庄磊靓 | 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 |
| EP3679053A4 (en) * | 2017-09-05 | 2021-10-27 | Mainline Biosciences | CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE |
| US11123437B2 (en) | 2017-09-05 | 2021-09-21 | Mainline Biosciences, Inc. | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
| US11771736B2 (en) * | 2017-12-21 | 2023-10-03 | Mainline Biosciences (Shanghai) Co., Ltd. | Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same |
| JP2021165234A (ja) * | 2018-07-03 | 2021-10-14 | 富士フイルム富山化学株式会社 | Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体 |
| WO2020053255A1 (en) | 2018-09-12 | 2020-03-19 | Technische Universität München | Therapeutic and diagnostic agents for cancer |
| US11944691B2 (en) | 2018-09-12 | 2024-04-02 | Technische Universität München | CXCR4-targeted diagnostic and therapeutic agents with reduced species selectivity |
| CN114364690A (zh) * | 2019-04-18 | 2022-04-15 | 省卫生服务机构 | 用于诊断和治疗的新型放射性标记的cxcr4靶向化合物 |
| CN115003684A (zh) * | 2020-01-26 | 2022-09-02 | 主线生物科学有限公司 | 同位素标记的选择性cxcr4结合肽偶联物及其制备和使用方法 |
| JPWO2022138891A1 (es) * | 2020-12-25 | 2022-06-30 | ||
| EP4043041A1 (en) | 2021-02-15 | 2022-08-17 | Technische Universität München | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof |
| AU2023257191A1 (en) * | 2022-04-20 | 2024-10-10 | Alpha-9 Oncology Inc. | Cxcr4-targeting compounds, and methods of making and using the same |
| CN115060901A (zh) * | 2022-06-21 | 2022-09-16 | 中国医学科学院基础医学研究所 | 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4391123B2 (ja) * | 2002-10-24 | 2009-12-24 | 株式会社オーファンリンク | 新規ｃｘｃｒ４アンタゴニスト |
| US8628750B2 (en) | 2006-02-27 | 2014-01-14 | Technische Universitat Munchen | Cancer imaging and treatment |
-
2008
- 2008-05-20 PL PL08769524T patent/PL2160221T3/pl unknown
- 2008-05-20 US US12/123,574 patent/US7691813B2/en not_active Ceased
- 2008-05-20 MY MYPI20095053A patent/MY149432A/en unknown
- 2008-05-20 PE PE2008000868A patent/PE20090299A1/es not_active Application Discontinuation
- 2008-05-20 CL CL2008001467A patent/CL2008001467A1/es unknown
- 2008-05-20 EA EA200971129A patent/EA017716B1/ru not_active IP Right Cessation
- 2008-05-20 AU AU2008260326A patent/AU2008260326B2/en not_active Ceased
- 2008-05-20 CN CN2008800178577A patent/CN101678213B/zh not_active Expired - Fee Related
- 2008-05-20 CA CA2688574A patent/CA2688574C/en not_active Expired - Fee Related
- 2008-05-20 KR KR1020117026680A patent/KR101319740B1/ko not_active IP Right Cessation
- 2008-05-20 JP JP2010510418A patent/JP5358564B2/ja not_active Expired - Fee Related
- 2008-05-20 NZ NZ580849A patent/NZ580849A/en not_active IP Right Cessation
- 2008-05-20 MX MX2009012952A patent/MX2009012952A/es active IP Right Grant
- 2008-05-20 EP EP11172401A patent/EP2377579A1/en not_active Withdrawn
- 2008-05-20 KR KR1020097024829A patent/KR101169846B1/ko not_active IP Right Cessation
- 2008-05-20 AT AT08769524T patent/ATE516853T1/de active
- 2008-05-20 BR BRPI0812134-6A2A patent/BRPI0812134A2/pt not_active IP Right Cessation
- 2008-05-20 WO PCT/US2008/064177 patent/WO2008150689A1/en active Application Filing
- 2008-05-20 JO JO2008229A patent/JO2776B1/en active
- 2008-05-20 EP EP08769524A patent/EP2160221B1/en active Active
- 2008-05-20 PT PT08769524T patent/PT2160221E/pt unknown
- 2008-05-20 DK DK08769524.3T patent/DK2160221T3/da active
- 2008-05-20 AR ARP080102137A patent/AR066648A1/es unknown
- 2008-05-20 TW TW097118554A patent/TWI423987B/zh not_active IP Right Cessation
-
2009
- 2009-10-22 IL IL201685A patent/IL201685A/en not_active IP Right Cessation
- 2009-11-10 CR CR11105A patent/CR11105A/es not_active Application Discontinuation
- 2009-11-25 ZA ZA2009/08345A patent/ZA200908345B/en unknown
- 2009-11-26 GT GT200900304A patent/GT200900304A/es unknown
- 2009-11-26 TN TNP2009000496A patent/TN2009000496A1/fr unknown
- 2009-11-27 CO CO09135750A patent/CO6241137A2/es active IP Right Grant
- 2009-11-27 DO DO2009000270A patent/DOP2009000270A/es unknown
- 2009-12-21 MA MA32439A patent/MA31666B1/fr unknown
-
2010
- 2010-01-25 US US12/692,788 patent/US20100130409A1/en not_active Abandoned
- 2010-08-20 HK HK10107961.8A patent/HK1141474A1/xx not_active IP Right Cessation
- 2010-09-10 US US12/807,694 patent/USRE42274E1/en not_active Expired - Fee Related
-
2011
- 2011-07-25 HR HR20110551T patent/HRP20110551T1/hr unknown
- 2011-09-07 CY CY20111100861T patent/CY1111815T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066648A1 (es) | Peptido ciclizado por lactamas, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de canceres artritis reumatica, fibrosis pulmonar e infeccion por vih | |
| Kosikowska et al. | Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015) | |
| ES2548767T3 (es) | Nuevos péptidos antimicrobianos | |
| JP2010529957A5 (es) | ||
| PE20180571A1 (es) | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| UA103882C2 (uk) | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина | |
| NZ601818A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
| CN113507962A (zh) | Mt1-mmp特异性的双环肽配体 | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| JP2011518179A5 (es) | ||
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| US12115224B2 (en) | Polypeptide conjugates for intracellular delivery of stapled peptides | |
| Lohani et al. | Solid-phase synthesis and in vitro biological activity of a Thr4→ Ser4 analog of daptomycin | |
| Xu et al. | A new strategy for total solid-phase synthesis of polymyxins | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| WO2021042039A1 (en) | Synthetic antimicrobial peptides | |
| Matheson et al. | Establishing the structure-activity relationship of teixobactin | |
| Koizumi et al. | Structure–activity relationship of cyclic pentapeptide malformins as fibrinolysis enhancers | |
| ES2719137T3 (es) | Análogos de apelina cíclica | |
| JP2018529625A5 (es) | ||
| NZ597777A (en) | Motilin-like peptide compound having transmucosal absorbability imparted thereto | |
| NO20082127L (no) | Antagonister mot interaksjon av PF4 og Rantes | |
| Nguyen et al. | Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |